Lung Cancer Clinical Trials in Baltimore, MD

Lung Cancer Clinical Trials in Baltimore, MD

View the best 10 lung cancer medical studies in Baltimore, Maryland. Access promising new therapies by applying to a Baltimore-based Lung Cancer clinical trial.

Trials in Baltimore, Maryland

Here are the top 10 medical studies for lung cancer in Baltimore, Maryland

Image of Research Site in San Diego, United States.

Durvalumab +2 More

Checkpoint Inhibitor

Recruiting1 awardPhase 3
This trial is testing two drug combinations to help the immune system fight advanced lung cancer that can't be surgically removed. The patients have already had previous treatment without their disease getting worse. The drugs aim to boost the immune response to better identify and kill cancer cells.
Image of University of Florida Health Science Center - Jacksonville in Jacksonville, United States.

Proton Beam Radiation Therapy +1 More

Proton Beam Therapy

Recruiting3 awardsPhase 3
This trial is comparing two types of radiation therapy to see which is more effective in treating patients with stage II-IIIB non-small cell lung cancer- proton chemoradiotherapy versus photon chemoradiotherapy.
Image of START Midwest in Grand Rapids, United States.

LY3962673

Monoclonal Antibodies

Recruiting1 awardPhase 1
This trial aims to test the safety and effectiveness of a drug called LY3962673 on its own and when used with other chemotherapy drugs in patients with a specific type of advanced solid tumors. The study
Image of Bryn Mawr Hospital in Bryn Mawr, United States.

Pembrolizumab

Monoclonal Antibodies

Recruiting2 awardsPhase 3
"This trial is comparing the benefits of using chemotherapy along with immunotherapy (pembrolizumab) versus just using immunotherapy alone to treat patients with advanced lung cancer. The goal is to see
Image of Research Site in Chandler, United States.

Docetaxel +2 More

Taxane

Recruiting3 awardsPhase 3
This trial tests a new combination of drugs (ceralasertib and durvalumab) against a standard treatment (docetaxel) in patients with advanced lung cancer who didn't respond to previous treatments. The new combination aims to weaken cancer cells and boost the immune system, while the standard treatment directly kills the cancer cells.
Image of University of Iowa in Iowa City, United States.

[212Pb]VMT-α-NET

Radioisotope Therapy

Recruiting1 awardPhase 1 & 2
This trial is testing a new therapy to treat advanced neuroendocrine tumors using targeted alpha-particles.
Image of University of California at Davis in Davis, United States.

ONC-392 +1 More

Monoclonal Antibodies

Recruiting1 awardPhase 1 & 2
This trial tests ONC-392, an antibody that helps the immune system fight cancer, in patients with advanced or spreading tumors who haven't responded to other treatments. It works by blocking a protein that usually keeps immune responses in check, making it easier for the body to attack cancer cells.
Image of Banner MD Anderson in Gilbert, United States.

APL-101

Small Molecule Inhibitor

Recruiting1 awardPhase 2
This trial is testing APL-101, a new drug, on patients with specific genetic changes in their cancer. These patients often don't respond to typical treatments. The drug aims to block a protein that helps cancer cells grow and spread.
Image of Alaska Oncology and Hematology in Anchorage, United States.

Docetaxel +1 More

Anti-microtubule agent

Recruiting2 awardsPhase 3
This trial is testing a new drug, sigvotatug vedotin, against a standard drug, docetaxel, in patients with advanced lung cancer. The goal is to see if the new drug works better and to understand its side effects. Docetaxel (Taxotere) is a well-established chemotherapy agent used in the treatment of advanced non-small cell lung cancer (NSCLC), often after failure of first-line treatments.
Image of Research Site in Vancouver, Canada.

Trastuzumab Deruxtecan

Monoclonal Antibodies

Recruiting2 awardsPhase 3
This trial will compare the effectiveness and safety of Trastuzumab Deruxtecan to the current standard of care for treating non-small cell lung cancer with HER2 Exon 19 or 20 mutations.

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.